Osteoporosis is a chronic, progressive skeletal disease characterized by low bone mass, microarchitecture deterioration of bone tissue, bone fragility, and a consequent increase in fracture risk.
Definition of Osteoporosis - Prevalence - Risk factors for Osteoporosis - Diagnosis of Osteoporosis - Clinical manifestations- Laboratory investigations - DEXA - T and Z score - Management of Osteoporosis - Prevention
Osteoporosis is a progressive systemic skeletal disease characterized by low bone mass and microarchitecture deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk.
Everything you should know about Osteoporosis?
What is Osteoporosis?
Osteoporosis is a disorder of bones characterized by low bone density and a deterioration of bone micro- architecture that enhances bone fragility and increases the risk of fracture
Osteoporosis becomes a serious health threat for aging men & postmenopausal women by predisposing them to an increased risk of fracture
Do you know that?
Osteoporosis is responsible for >1.5 million vertebral and non-vertebral fractures per year
Spine, hip, and wrist fractures are most common.
This presentation includes four major topics:
1- reviews the essentials of osteoporosis including definition, pathophysiology, etiology, epidemiology, and prognosis
2- talks about the presentation of osteoporosis, including risk factors, symptoms and signs, radiologic manifestations, and complications
3- reviews the workup process to diagnose and define the severity of osteoporosis, including the lab. and radiologic procedures
4- reviews management tools of osteoporosis, including pharmacologic and non pharmacologic methods, with brief description for each pharmacologic or non pharmacologic tool.
Finally, some statements about the education and prevention of osteoporosis.
Definition of Osteoporosis - Prevalence - Risk factors for Osteoporosis - Diagnosis of Osteoporosis - Clinical manifestations- Laboratory investigations - DEXA - T and Z score - Management of Osteoporosis - Prevention
Osteoporosis is a progressive systemic skeletal disease characterized by low bone mass and microarchitecture deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk.
Everything you should know about Osteoporosis?
What is Osteoporosis?
Osteoporosis is a disorder of bones characterized by low bone density and a deterioration of bone micro- architecture that enhances bone fragility and increases the risk of fracture
Osteoporosis becomes a serious health threat for aging men & postmenopausal women by predisposing them to an increased risk of fracture
Do you know that?
Osteoporosis is responsible for >1.5 million vertebral and non-vertebral fractures per year
Spine, hip, and wrist fractures are most common.
This presentation includes four major topics:
1- reviews the essentials of osteoporosis including definition, pathophysiology, etiology, epidemiology, and prognosis
2- talks about the presentation of osteoporosis, including risk factors, symptoms and signs, radiologic manifestations, and complications
3- reviews the workup process to diagnose and define the severity of osteoporosis, including the lab. and radiologic procedures
4- reviews management tools of osteoporosis, including pharmacologic and non pharmacologic methods, with brief description for each pharmacologic or non pharmacologic tool.
Finally, some statements about the education and prevention of osteoporosis.
This was a lecture in the course "Significant Medical Conditions in Seniors" presented at Peer Learning in Chapel Hill, NC, USA in 2016 by Michael C. Joseph, MD, MPH.
For info log on to www.healthlibrary.com. Osteoporosis of Bones By Dr. Prakash Khalap
OSTEOPOROSIS which is more in Elderly, Osteoporosis is Common in both females and males after 60 yrs. Fractures, reduction in height, Backache, vague Pain of body are common symptoms which many elderly suffers unknowingly.
Osteoporosis: Classification, Causes, Symptoms, Treatment & Prevention
In this article, we’ll discuss what osteoporosis is, osteoporosis definition, osteoporosis types, osteoporosis causes, osteoporosis symptoms, osteoporosis medicine, osteoporosis treatment and osteoporosis prevention.
Osteoporosis:
Osteoporosis is a condition of low bone mass and decay of bone tissue prompting bone delicacy and conceivably breaking with numerous preventable and intrinsic danger factors. Osteoporosis influences bones and makes them more defenseless against sudden and unanticipated breaks and breakage. The term osteoporosis is derived from the Greek words osteon (bone) and poros (pore). For complete article, click on the given link, https://diseases8804.blogspot.com/2021/08/all-you-need-to-learn-about-osteoporosis.html
OSTEOPOROSIS:A Barebone guide to diagnosis and managementGovindRankawat1
“Progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk”
True Definition: bone with lower density and higher fracture risk
WHO: utilizes Bone Mineral Density as definition (T score <-2.5)
Osteoporosis is silent because there are no symptoms initially.
The most common are fractures of the spine, hip, and wrist.
Osteoporosis is not an inevitable part of aging, but is a disease that can be prevented and treated, provided it is detected early.
The main goal of treating osteoporosis is to prevent such fractures in the first place.
Bare bone term used for “necked bone with necked eye”
“There is clearly a problem of underdiagnosis and undertreatment of osteoporosis and we want to raise awareness about the risk factors for osteoporosis so that those who need treatment get treatment”.
Learning Objectives
Utilize recent recommendations for osteoporosis prevention and treatment and how to apply them in practice.
Explain controversies surrounding pharmacologic osteoporosis therapy including side effects and the risk/benefit ratio of therapy.
Determine when and how to utilize the current pharmacologic therapies including anabolic versus anti-resorptive approaches and how to transition or discontinue treatment
Osteoporosis only causes symptoms when it is far advanced.
Symptoms include loss of height, deformed spine (“dowager’s hump”), unexplained back pain, and fractures.
It is best to detect problems at an early stage, when treatment is most effective.
The best test for detecting osteoporosis is bone densitometry, done with a technique called “Dual-energy X-ray Absorptiometry” or DXA.
Similar to Osteoporosis in Elderly People.pptx (20)
The Comprehensive Geriatric Assessment.pptxAhmed Mshari
Comprehensive Geriatric Assessment (CGA) is a process of care comprising a number of steps. Initially, a multidimensional holistic assessment of an older person considers health and wellbeing and leads to the formulation of a plan to address issues which are of concern to the older person (and their family and carers when relevant). Interventions are then arranged in support of the plan. Progress is reviewed and the original plan reassessed at appropriate intervals with the interventions reconsidered accordingly.
Helicobacter pylori (H. pylori) has so far infected more than half the global population. It is the most important and controllable risk factor for gastric cancer. The elderly, who are at a higher incidence of the infection, are also commonly found to develop antibiotic resistance. The symptoms, diagnosis, clinical features (of gastric or extra-digestive diseases), and treatment of H. pylori infection in the elderly, are different from that in the non-elderly. Health conditions, including comorbidities and combined medication have limited the use of regular therapies in elderly patients. However, they can still benefit from eradication therapy, thus preventing gastric mucosal lesions and gastric cancer. In addition, new approaches, such as dual therapy and complementary therapy, have the potential to treat older patients with H. pylori infection.
DYSLIPIDAEMIA Management the European approach.pptxAhmed Mshari
Atherosclerotic cardiovascular diseases are responsible for millions of deaths worldwide each year.
More patients are surviving their first CVD event and are at high-risk of recurrences.
The prevalence of some risk factors, notably diabetes and obesity, is increasing.
In recent years, a number of international and regional guidelines were developed to deal with this problem.
Frailty is a common clinical syndrome in older adults.
It is a risk factor for many health problems that older adults face.
Frailty is a major focus of geriatrics medicine.
This lecture will review the definition, epidemiology, etiologies, and consequences of frailty.
It will also discuss how to identify and manage frail older adults.
PHC represents a philosophical approach to health and health care.
This approach is characterized by a holistic understanding of health as well-being, rather than the absence of disease.
It integrates knowledge of the medical, biological, physical, social, psychological, and behavioral sciences.
PHC provides a comprehensive care including health promotion, illness prevention, treatment and care of the sick, and rehabilitation.
Polypharmacy and Rational Prescribing in Elderly Patients.pptxAhmed Mshari
Polypharmacy is typically defined as the prescription of five or more medications.
It also refers to the prescription of medications that do not have a specific current indication, that duplicate other medications, or that are known to be ineffective for the condition being treated.
In other words, polypharmacy is the use of multiple medications that are unnecessary and have the potential to do more harm than good.
Injurious falls is a true geriatric syndrome and serious clinical problems facing older adults.
Falls result in significant morbidity and mortality and an increased rate of nursing home placement.
هو نهج جديد يتم تطبيقه في بعض مراكز الرعاية الصحية الأولية، يهدف الى دعم وتحسين نظام الرعاية الصحية الأولية والمساهمة بتوفير حزمة الخدمات الصحية الأساسية بجودة عالية، وبتكلفة يسيرة، ومستندة الى الأدلة العلمية المحدثة.
Depression in elderly people, also known as late-life depression, is a clinical syndrome characterized by persistent feelings of sadness, loss of interest or pleasure in activities, and a range of emotional, cognitive, and physical symptoms that significantly impact the individual's functioning and quality of life.
Insulin has three characteristics:
Onset: is the length of time before insulin reaches the bloodstream and begins lowering blood glucose.
Peak time: is the time during which insulin is at maximum strength in terms of lowering blood glucose.
Duration: is how long insulin continues to lower blood glucose.
Constipation is one of the most frequent GIT disorders encountered among older adults in clinical practice.
Up to 50% of elderly experiencing constipation at some point in their lives.
Elderly women are having 2–3 times more constipation than men.
Approximately, 30% of older adults are regular nonprescription laxative users, such as stimulant and bulking laxatives.
In this overview, we draw inspiration from the article titled "Managing Hypertension in Primary Care“, published in the Canadian Family Physician journal (Vol 65: October 2019).
The article, edited by Khrystine Waked PharmD, Jeff Nagge PharmD, and Kelly Grindrod PharmD MSc,.
It provides valuable insights and evidence-based approaches to tackle Hypertension Management In Primary Care.
By incorporating the recommendations discussed in this article, we can enhance our ability to manage hypertension and ultimately improving patient outcomes and quality of life.
المداخلات المبسطة للتحرر من التبغ.pptxAhmed Mshari
التدخين هو عملية يتم فيها حرق مادة التبغ وإستنشاقه.
يعتبر التدخين واحداً من أسوأ الأختراعات التي عرفها التاريخ ومن أهم المشاكل التي تواجه مجتمعات العالم وخاصة النامية منها.
لوحظ تسارع إنتشار هذه الظاهرة بين الفئات العمرية كافة وخاصة فئة الشباب والمراهقين وبين أوساط النساء أيضاً.
إن ضرره يتعدى الجانب الصحي, فهو يساهم بحدوث أضرار بيئية وأجتماعية وأقتصادية كبيرة.
To the consultation, the patient brings ideas, concerns, expectations, feelings and emotions related to his health problem. These areas are often grouped together and called the “Patent’s Agenda”.
Some of these emotional concerns may be explicit “Open Agenda”, but a large part may never be expressed openly if doctors do not proactively elicit them.
In 1981, Barsky, an American psychiatrist, gave a name to this assortment of hidden concerns; he called it the “Hidden Agenda”.
An important objective of a medical consultation is to understand as much as possible these hidden emotions.
Unless the doctor is able to fathom these, the patient may only be left with therapy that will treat his most obvious symptoms but not resolve the underlying problems.
Referral Process in Family Practice.pptxAhmed Mshari
It the process that involve seeking the assistance of another specialist with a resource to guide in managing a specific problem and sharing responsibility in patient care.
Ideally, it would result in “a closed referral loop”, in which the referral appointment is completed and results are then shared with the patient’s referring physician.
Apart from consultants and hospitals, a referral might be considered to family physician colleagues with special interests or expertise, and other members of the primary health care team, such as physiotherapists, dietitians, and social workers.
Ethical Issues in Obtaining Informed Consent.pptxAhmed Mshari
Medical ethics is a set of moral principles, beliefs and values that guide decisions about patient care.
It is an integral part of good medical practice.
The health care professional uses knowledge, experience, and judgment and considers the ethical principles to make decisions on management recommendations.
Medical errors are a growing concern in health care organizations.
No matter how well trained or hard working, healthcare providers make mistakes, just like other professionals.
Some data suggest that medical errors occurs up to 80 times per 100,000 consultations.
Medical errors are the third leading cause of death in the United States.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
2. Define osteoporosis and identify its
classes.
Discuss the prevalence and impact
of osteoporosis in the elderly.
Identify key risk factors contributing
to osteoporosis development in the
elderly.
Recognize and describe clinical
features associated with
osteoporosis.
Understand the significance of
measuring bone mineral density in
diagnosing and assessing
osteoporosis risk.
Apply recommended guidelines for
assessing osteoporosis risk in the
elderly.
Discuss strategies for preventing
osteoporosis and fractures.
Discuss established treatment
strategies.
Explain the mechanism of action,
role, benefits, and risks of
Bisphosphonates in osteoporosis
treatment.
Understand the importance of
regular patient monitoring during
osteoporosis treatment.
3. Osteoporosis is a chronic, progressive
skeletal disease characterized by low bone
mass, microarchitecture deterioration of
bone tissue, bone fragility, and a
consequent increase in fracture risk.
The National Osteoporosis Foundation
4. There are 44 million Americans have low
bone mass, and 10 million have
osteoporosis.
Osteoporosis affects about 50% of women
and 20% of men older than 50 years.
Its prevalence increases from 8% in the
seventh decade to 47.5% in the ninth
decade.
Two million osteoporotic fractures occur
each year.
The overall prevalence of fragility
fractures is higher in women.
Vertebral fractures are the most
prevalent of all fragility fractures.
Only 1/3 of vertebral fractures receive
medical attention.
There are almost 300,000 hip fractures
annually.
Hip fractures are associated with the
most serious outcomes:
> 20% of patients dying during the first
year.
> 40% of them are unable to return to
their previous ambulatory state.
> 20% of them are placed in long-term
care facilities.
Hip fractures contribute more to
significant health care expenditure.
5. Bone is continuously undergoing a remodeling
process called Bone Turnover.
This involves both bone formation and
resorption.
Osteoblasts are responsible for bone
formation, synthesizing new bone tissue by
depositing collagen and minerals.
Osteoclasts are responsible for bone
resorption, breaking down old or damaged
bone tissue and releasing calcium and minerals
into the bloodstream.
Remodeling allows bones to adapt to changing
mechanical demands, repair micro-damage,
and maintain mineral balance in the body.
6. Bone remodeling is a dynamic process
influenced by mechanical stress on
bones and hormonal regulation.
It is tightly regulated by Parathyroid
hormone and Calcitonin.
PTH stimulates bone resorption to
release calcium into the bloodstream.
Calcitonin inhibits bone resorption,
promoting calcium deposition in bones.
Sex hormones (Estrogen and
Testosterone) have a protective role in
maintaining bone density.
7. Postmenopausal.
Involutional or Senile
Osteoporosis.
Secondary to
various causes and
risk factors.
Secondary
Osteoporosis
Primary
Osteoporosis
8. Age
Gender
Family history and
genetics
Race and ethnicity
Previous fractures
Body size
Non-Modifiable
Nutrition (Calcium,
Vitamin D Intake)
Physical activity and
exercise
Smoking and excessive
alcohol consumption
Medications
Hormonal imbalance
Modifiable
10. Fragility fractures have a
significant impact on the quality
of life and functionality of
Patients.
These fractures often occur as a
result of minimal trauma or falls,
and their consequences can be
severe and long-lasting.
They are commonly affected the
hip, spine (vertebral
compression fractures), and
wrist (distal radius fractures).
Complications of Osteoporosis
11. Hip fractures: They can lead to a significant
loss of independence and mobility. Many
require surgical intervention and
rehabilitation, and some may never regain
previous level of function.
Vertebral compression fractures: They can
cause chronic back pain and a decrease in
height, kyphosis which can further impact
mobility and balance.
Wrist fractures: They can result in impaired
upper limb function and limit an individual's
ability to perform daily tasks independently.
12. Osteoporosis is generally asymptomatic until
fractures occur.
Fractures of the forearm and hip are usually easy to
diagnose, but vertebral fractures are difficult to
detect clinically.
About 90% of hip fractures occur after a fall.
2/3 of vertebral fractures are silent and occur with
minimal stress, such as lifting, sneezing, or bending.
Vertebral fractures may cause an acute episode of
back pain lasting for 6-8 weeks before settling to a
more chronic backache.
Vertebral fractures cause height loss, kyphosis, and
severe cervical lordosis.
13. Clinical findings can significantly increase the
suspicion of osteoporosis or spinal fracture and
identify individuals may benefit from earlier
screening, including:
Low body weight (<51 kg).
Inability to place the back of the head against a
wall when standing upright (humped back).
Low tooth count (<20).
Rib-pelvis distance ≤2 fingerbreadths.
Loss of height >3 cm.
Physical exam should also focus on secondary
causes of osteoporosis.
14. Dual energy X-ray
absorptiometry (DXA) is the
gold standard for the diagnosis
of osteoporosis.
It assesses the bone mass at
lumbar spine, hip and wrist.
Bone mass is measured as bone
mineral density (BMD) in g/cm2.
The BMD ‘T-Score’ is the number
of SD away from the mean BMD
of a 30-year-old adult of the
same sex.
Each SD change of BMD
increases fracture risk by 2-3
times.
15. 1. Determine BMD.
2. Estimate fracture risk.
3. Identify candidates
for intervention.
4. Assess changes in
bone mass over time
in treated and
untreated patients.
DXA scan
Benefits
16. T-Score
Category Definition by Bone Density
Normal T-Score is greater than −1.0
Osteopenia T-Score is −1 to −2.5
Osteoporosis T-Score is less than −2.5
Severe
osteoporosis
T-Score is less than −2.5
with 1 or more fragility fractures
18. All men ≥ 70-year-old
Younger men with
clinical risk factors
for fracture.
Screening Guidelines for
Assessing Osteoporosis Risk
All women ≥ 65-year-old.
Younger and
perimenopausal women
with risk factors for
fragility fractures.
19. FRAX is an accessible online
algorithm developed by WHO.
It aimed to calculate a patient’s
10-year probability of a fragility
fracture.
It uses some of the clinical risk
factors and BMD measurements.
It also uses country-specific
fracture data.
It is used for untreated
patients only.
It is applicable to both women
and men ages 40-90 years.
About the Risk Factors
21. All older patients should
have a S. Ca level, 25-
hydroxy vitamin D, and
PTH assessment.
Basic chemistry panel;
CBC; RFT and LFT.
Rule out common
secondary causes of
osteoporosis.
22. Modify secondary causes of osteoporosis
Adequate Calcium and vitamin D intake
Regular weight-bearing, muscle
strengthening exercise
Prevent falls
Correct vision and hearing
Evaluate gait and balance
Assess medication side effects
Evaluate home safety
Hip protectors if high fall risk
Quit smoking and limit alcohol and caffeine
intake
Prevention of Osteoporosis
and Fractures
23. NOF and IOM recommended:
Men age 50-70 consume 1000 mg/day
Women ≥ 51 years and men ≥ 71 years
consume 1200 mg/day of calcium.
Intakes in excess of 1200-1500 mg/day
increase the risk of kidney stones and
CVD.
The average daily dietary calcium intake
in adults ≥ 50 years is 600-700 mg/day.
Calcium supplements should be used
when an adequate dietary intake cannot
be achieved.
24. Vitamin D plays a major role in
calcium absorption, bone
health, muscle performance,
balance, and risk of falling.
Vitamin D deficiency is associated
with muscle weakness and falls.
Vitamin D status can be evaluated
by measuring serum 25-hydroxy
vitamin D.
30
0
10
20
40
50
60
70
80
90
100
Deficient
Ideal
Risk of Toxicity
Blood Level of Vitamin D (ng/ml)
Insufficient
25. IOM recommends a dietary allowance of
vitamin D:
600 IU/day for people ≤ 70 years old.
800 IU/day for those >70 years old.
NOF recommends an intake of 800-1000
IU/day of vitamin D for adults ≥50 years
old.
Supplementation with vitamin D2
(Ergocalciferol) or vitamin D3
(Cholecalciferol) may be used.
Patients receiving treatment for
osteoporosis are offered concomitant
Calcium and Vitamin D supplementation.
26. Many older patients are at high risk for Vitamin D
deficiency:
Patients with malabsorption (celiac disease) or
other intestinal diseases (IBD, gastric bypass
surgery).
Chronic renal insufficiency.
Patients on medications that increase the
breakdown of Vitamin D (some antiseizure drugs).
People with limited sun exposure, housebound
patients, individuals with very dark skin.
Chronically ill patients.
Obese individuals.
27. Treatment of vitamin D
deficiency may be done with
50,000 IU of Vit. D2 or vit. D3
once a week or the equivalent
daily dose for 8-12 weeks to
achieve a S. 25(OH)D level of
approximately 30 ng/ml.
This regimen should be followed
by maintenance therapy of 1000-
2000 IU/day to maintain the
target blood level (30 ng/ml).
5
20
30
10
28. Calcium Homeostasis explaining how
the body maintains calcium levels.
When blood calcium levels are low,
the Parathyroid hormone promotes:
Absorption of calcium in the
intestine.
Conservation of calcium by the
kidneys.
Release of calcium from bone
tissue.
When blood calcium levels are high,
the Calcitonin hormone promotes:
Elimination of calcium by the
kidneys.
Storage of calcium in bone tissue.
29. 1. An adult hip or vertebral fragility
fracture.
2. T-score ≤ −2.5 for lumbar spine, total
hip, or femoral neck after
appropriate evaluation to exclude
secondary causes.
3. T-scores between (−1.0 and −2.5) at
the lumbar spine or femoral neck
and a FRAX 10-year probability of a
hip fracture ≥3% or a 10-year
probability of major osteoporosis-
related fractures ≥20%.
30. A number of pharmacological agents have been developed to treat
osteoporosis.
There are a number of side effects and potential long-term risks that
dictate the need for proper selection and individualized treatment.
Treatment guidelines recommend using BISPHOSPHONATES as first
line of treatment.
The other drugs are used to individuals who are not responding or
cannot tolerate bisphosphonate.
All patients who are started on treatment for osteoporosis should
also receive adequate intake of Calcium and Vitamin D
supplementation.
31. Current osteoporosis therapy are
divided into Antiresorptive and
Anabolic agents.
Antiresorptive therapy available now:
Bisphosphonates.
Hormone replacement therapy.
Raloxifene.
Denosumab.
Calcitonin.
Parathyroid hormone is the only
anabolic agent available now.
32. Bisphosphonates (BPs) are the mainstay of
osteoporosis prevention and treatment.
They have a proven antifracture efficacy
and good safety profile.
They reduce risk of vertebral, hip, and
other fractures.
They are potent antiresorptive agents by
inhibiting osteoclastic activity.
They are contraindicated with eGFR below
30 ml/min.
Prior to initiating therapy, Calcium and
Vitamin D must be adequately replenished
due to avoid possibility of hypocalcemia.
BISPHOSPHONATES
for strong bones
33. Following administration, BPs
target bone surfaces and are
ingested by osteoclasts during
the process of bone resorption.
Then BPs are released within
the osteoclasts and impairs
bone resorption.
The skeletal benefits may be
preserved for at least 1–2 years
after cessation of treatment.
Mechanism of Action
of Bisphosphonates
34. FDA approved the following agents:
Alendronate, Risedronate,
Ibandronate and Zoledronic acid.
BPs may be given as:
Orally:
Daily (Alendronate, Risedronate).
Weekly (Alendronate, Risedronate).
Monthly (Risedronate, Ibandronate).
Intravenously:
Every 3 months (Ibandronate).
Once yearly (Zoledronic acid).
It is recommended that
patients be reevaluated after
5 years of oral or 3 years of
intravenous BPs therapy.
If they are osteopenic and
without fracture risk, they
can begin a BPs holiday, and
reevaluation in 1-2 years.
Oral BPs may be continued
for up to 10 years in patients
whose BMD levels remain in
the osteoporotic range after 5
years.
35. Alendronate can increase BMD by about
8% at the spine and 4% at the hip over 3
years.
It reduces the incidence of spine, hip, and
forearm fractures by about 50 % over 3
years.
It is the most commonly used because it
is the least expensive.
It is prescribed as:
5 mg daily, 35 mg weekly tablets, for
the prevention of osteoporosis.
10 mg daily tablet, 70 mg weekly tablet,
for the treatment of osteoporosis.
36. Oral BPs must be taken first thing
in the morning on an empty
stomach with a full glass of water
because of their poor absorption.
Patients must sit upright for 30
minutes (with alendronate and
risedronate), to 60 minutes (with
ibandronate) ingesting other
medication or food and must not lie
down.
37. Common:
Upper GI intolerance (oral).
Flu-like symptoms (IV).
Less common:
Atrial fibrillation (IV Zoledronic
acid).
Hypocalcemia (IV).
Atypical femoral shaft fractures.
Rare:
Osteonecrosis of the jaw.
Esophageal ulceration.
Adverse Effects of
Bisphosphonates
38. HRT (Estrogen and Progestogen) is
primarily indicated for the treatment of
moderate-severe menopausal
symptoms.
It is also approved for the prevention of
osteoporosis in postmenopausal
women.
It prevents bone loss and reduces the
risk of fragility fractures in post-
menopausal women.
The Women’s Health Initiative Study
recommended NOT to be used above
the age of 60 because of an increased
risk of breast cancer, CVD and venous
thromboembolic disease.
Hormone
Replacement
Therapy
39. It is a selective estrogen receptor modulator.
It has estrogen agonist actions on the
skeleton BUT estrogen antagonist actions on
the breast and endometrium.
It is effective at reducing vertebral fractures
only.
It is generally used in postmenopausal women
with osteoporosis who are unable to tolerate
BPs and have a high breast cancer risk.
It increases risk of venous thromboembolism.
It can be given orally in dose of 60 mg/day.
Bazedoxifene is a selective estrogen receptor
modulator more recently approved for use in
the prevention of osteoporosis.
40. Teriparatide is a recombinant human (synthetic) PTH.
It has anabolic actions on the skeleton if given as daily
S/C injection.
It decreases fragility fractures.
It is given in dosage of 20 mcg/day for up to 2 years.
It is approved for the treatment of:
Postmenopausal women with severe bone loss.
Men with osteoporosis who have high risk of fracture.
Individuals whose condition has not improved with Bps
therapy.
One study suggests to follow Teriparatide therapy with
Bps to maintain BMD gains.
41. It is a human monoclonal antibody
that inhibits the activity of osteoclasts.
It has been shown to decrease fragility
fractures.
It significantly increased BMD in
postmenopausal women.
It is also given to persons who doesn’t
improve with BPs.
It is given S/C in a dose of 60 mg every
6 months for 3 years.
It may cause hypocalcemia, that can
be mitigated by calcium and vitamin D
supplements.
42. It has a direct inhibitory effects on osteoclastic
bone resorption.
It reduces the occurrence of vertebral
compression fractures only.
It is approved for the treatment of osteoporosis
in women who are at least 5 years
postmenopausal.
It is an option for women who cannot tolerate
BPs or SERMs.
It may reduce pain following an acute vertebral
compression fracture.
Calcitonin nasal spray is generally administered
once per day.
43. Osteoporosis is a chronic disease and
requires lifelong management and follow-up.
No pharmacologic therapy should be
considered indefinite in duration.
Duration decisions need to be individualized.
Evidence of efficacy beyond 5 years is
limited.
Osteonecrosis of the jaw and atypical femur
fractures are more common beyond 5 years.
All non-bisphosphonate medications produce
temporary effects that wane upon
discontinuation.
BPs may allow residual effects even after
treatment discontinuation.
Panoramic radiograph:
Patient: 48 years old, female, metastatic
breast cancer on zoledronic acid (Zometa).
44. Osteoporosis medications
should be reviewed annually.
Encourage the followings:
Appropriate treatment
compliance.
Appropriate calcium and
vitamin D intakes.
Exercise, fall prevention, and
other lifestyle measures.
Reevaluation of the patient.
Reevaluation includes:
Interval clinical history
(intercurrent fracture history
and new chronic diseases or
medications use).
Height measurement is a critical
determination of osteoporosis
treatment efficacy.
Serial DXA testing.
Vertebral imaging if there has
been any documented height
loss during the treatment
period.
Testing biochemical markers.
45. Serial DXA testing is an important
component of osteoporosis
management.
Perform BMD testing 1-2 years after
initiating therapy and every 2 years
thereafter.
More frequent BMD testing may be
warranted in patients at higher risk
of bone loss.
The interval may be longer for
patients without major risk factors
and who have an initial T-score in
the normal or upper low bone mass
range.
46. Biochemical markers of bone
remodeling include:
Resorption markers: serum
C-telopeptide (CTX) and urinary
N-telopeptide (NTX).
Formation markers: serum
bone-specific alkaline
phosphatase (BSAP), osteocalcin
(OC), and aminoterminal
propeptide of type I procollagen
(PINP).
Samples obtained in the early
morning after an overnight fast.
Biochemical markers are helpful in:
Predict risk of fracture in
untreated patients.
Predict rapidity of bone loss in
untreated patients
Predict extent of fracture risk
reduction when repeated after 3-6
months of treatment.
Predict magnitude of BMD
increases with therapies.
Determine adequacy of patient
compliance with osteoporosis
therapy.
Determine duration of “drug
holiday” and when and if
medication should be restarted.
47. Integrate osteoporosis awareness into
geriatric practice for comprehensive
patient care.
Prioritize timely osteoporosis diagnosis
through risk assessment and bone
density evaluations.
Make treatment decisions based on
evidence and patient-specific factors
for optimal outcomes.
Educate patients about adherence,
lifestyle adjustments, and fall
prevention for active participation in
bone health.
Consider future research opportunities
to advance geriatric osteoporosis
management and enhance patient
well-being.
48. Young, J. B. (2016). Brocklehurst’s Textbook of Geriatric Medicine and
Gerontology. Butterworth-Heinemann.
Wing, E. J., Fidsa, E. J. W. M. F., Schiffman, F. J., & Macp, F. J. S. M. (2021). Cecil
Essentials of medicine.
Conant, R., Williams, B., Chen, H., Landefeld, C. S., Ahalt, C., & Chang, A.
(2014). Current Diagnosis and Treatment: Geriatrics 2E. McGraw-Hill
Education / Medical.
Ralston, S. H., Penman, I. D., Strachan, M. W. J., & Hobson, R. P. (2018).
Davidson’s principles and practice of medicine.
Ham, R. J., Sloane, P. D., Warshaw, G. A., Potter, J. F., & Flaherty, E. (2014).
Ham’s primary care geriatrics: A Case-based Approach. Saunders.
Murtagh, J. (2015). John Murtagh’s general practice.
Cosman, F., De Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall,
S., & Lindsay, R. (2014). Clinician’s Guide to Prevention and Treatment of
Osteoporosis. Osteoporosis International, 25(10), 2359–2381.
Sweet, M. G., Sweet, J. M., Jeremiah, M. P., & Galazka, S. S. (2009). Diagnosis
and treatment of osteoporosis. American family physician, 79(3), 193–200.